Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | RAF1 | P04049 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240824 | 0.93 | MAPK14 (0.69) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2240817 | 0.92 | MAPK14 (0.81) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2239198 | 0.91 | BRAF (0.65) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2243737 | 0.90 | BRAF (0.74) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2242903 | 0.90 | FLT3 (0.57) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2243935 | 0.90 | MAPK14 (0.72) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2243085 | 0.90 | BRAF (0.84) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2243634 | 0.89 | MAPK14 (0.68) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2240890 | 0.89 | BRAF (0.74) | BRAFMAPK14MAPK13ABL1AXL | |
| SCHEMBL2239350 | 0.88 | MAPK14 (0.61) | BRAFMAPK14MAPK13ABL1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | BRAF 338/4885MAPK14 3645/4885MAPK13 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.